About Us
Hongmili China Lipid Patient Network is a patient-led peer support community founded in April 2020 by Ms. Nazhen Chen, a patient with heterozygous familial hypercholesterolemia (FH). Initially serving as a communication platform for FH patients to share research, treatment, and reimbursement policies, we have now evolved into a hub patient organization for inherited lipid disorders, expanding our support to include sitosterolemia, Familial Chylomicronemia Syndrome (FCS), and elevated Lp(a).
We drive patient-perspective real-world evidence (RWE) through continuous patient registries, presenting the real-life experiences of our community to stakeholders. We conduct patient education and public awareness campaigns, support basic and clinical research via dedicated research funds, and actively engage in policy advocacy to accelerate drug approval and improve protection mechanisms. We are also active members of global FH and cardiovascular patient networks.
Vision
A world where no one is threatened by inherited lipid disorders, and everyone can live a healthy and equal life.
Mission
To generate real-world evidence, influence policy and regulation, accelerate access to innovative therapies, and drive early diagnosis for patients with rare lipid disorders.
Values
Patient-oriented Evidence-Based Action-Oriented Transparent&Trustworthy
Jenna, ChenFounder of Homy FH China Patient Network
Ya-Ni WangAcademic Project Manager of Homy FH China Patient Network
Meng LiProject Manager of Homy FH China Patient Network
Yun SongResearcher of homy FH China Patient NetWork
Meng YuanDigital Media Operations Manager of Homy FH China Patient Network
Our focus
Advance research and support HoFH patients in accessing effective treatments to prevent cardiovascular events.
Advocate for screening policies and promote timely diagnosis, awareness, and proactive intervention for HeFH patients.
